Essential Premium

RTW and Rivals Cash In as Biopharma Roars Back

FDA leadership changes, consolidation, and new product launches have fueled a biotech rally, turning life sciences hedge funds into standout performers.

Renaissance Suffers Huge Losses in October

This is the quant firm’s biggest setback since founder Jim Simons died in 2024.

Sponsored

How Fed Policy Can Impact Corporate Bond Spreads

The Problem With VC: It's All Going to AI

Retail, consumer, and application software startups starve while money floods AI.

Related Content

Janus Henderson Maintains Its Wide Lead in Biotech

Steve Taub

Renaissance’s Medallion Fund Surged 76% in 2020. But Funds Open to Outsiders Tanked.

Michelle Celarier

For Some Hedge Funds, Venture Capital Is Back

Steve Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram